Back to School: How biopharma can reboot drug development. Access exclusive analysis here

EPS watch

EPS watch

Company 1Q09 EPS est 1Q09 EPS actual Outcome Growth from 1Q08 4/24 cls Wk chg % chg Mcap chg 4/24 Mcap
Actelion Ltd. (SIX:ATLN) NA CHF0.83 NA 131% CHF 51.30 CHF 2.38 5% $181.2 $5,486.7
First quarter revenues came in at CHF405.6M ($356M), up 27% in local currencies compared to CHF321.6M. Sales of Tracleer bosentan for pulmonary arterial hypertension (PAH) were CHF352.2M ($309.1M), up from CHF287.6M in 1Q08. The company reiterated 2009 guidance for revenue growth of 12-15% in local currencies.
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) $0.14 $0.16 Beat by $0.02 NA $34.19 -$0.75 -2%

Read the full 1240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers